Urological Associations recommends combining the Penile Traction Devices of Andromedical with Collagenase injections to treat Peyronie.
2019 New Treatment Guidelines for Peyronie's Disease
Urological Associations recommends combining the Penile Traction Devices of Andromedical with Collagenase injections to treat Peyronie.
NEW YORK, November 29, 2018 (Newswire.com) - Andromedical Laboratory has patented and researched Penile Traction Devices for 20 years to develop ANDROPEYRONIE ®, a medical device to treat Peyronie's disease. Based on a clinical study published in The Journal of Sexual Medicine (Nov-2013, Dr. Martínez-Salamanca et al.), ANDROPEYRONIE ® reduces the penile curvature in more than 50 percent, with a pain reduction, an increasing in penile length of 1.5 cm and an improvement in the sexual function. ANDROPEYRONIE ® is the only device registered by the U.S. Food and Drug Administration for PD. More information in: https://www.andropeyronie.com
The new guidelines, presented by the Canadian Urological Association (CUA) in 2018, recommend the use of remodeling technique based on Penile Traction Device of Andromedical (ANDROPEYRONIE®) in combination with collagenase injections to treat patients with Peyronie's disease (PD).